Tetrahydrobiopterin attenuates homocysteine induced endothelial dysfunction

Area of Science:

• Cardiovascular Research
• Endothelial Function
• Vascular Biology

Background:

• Homocysteine is a risk factor for atherosclerotic vascular disease.
• It impairs endothelial function by increasing superoxide and decreasing nitric oxide (NO).
• Tetrahydrobiopterin (BH4) is crucial for NO synthesis by nitric oxide synthase.

Purpose of the Study:

• To investigate the protective effects of BH4 against homocysteine-induced endothelial dysfunction.
• To determine if BH4 can restore NO production and reduce superoxide levels in hyperhomocysteinemia.

Main Methods:

• Isolated rat aortic segments were exposed to homocysteine with or without BH4 to assess vasorelaxation.
• Human umbilical vein endothelial cells were treated with homocysteine and BH4 to measure NO and superoxide production.
• Lucigenin chemiluminescence was used to quantify superoxide release.

Main Results:

• Homocysteine impaired endothelium-dependent and -independent vasorelaxation, an effect attenuated by BH4.
• Homocysteine increased superoxide production and decreased NO release in endothelial cells, effects mitigated by BH4.
• BH4 partially restored endothelial function and normalized NO/superoxide balance.

Conclusions:

• Hyperhomocysteinemia impairs endothelial function by reducing BH4 bioavailability, leading to nitric oxide synthase uncoupling.
• BH4 supplementation may be a therapeutic strategy to improve endothelial dysfunction in conditions of hyperhomocysteinemia.